Tumor Immunology and Immunotherapy - Integrated Methods Part A

<p>1. High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers<br>Grace Banik, Courtney B. Betts, Shannon M. Liudahl, Shamilene Sivagnanam, Rie Kawashima, Tiziana Cotechini, William Larson, Jeremy Goecks, Sara I. Pai, Daniel R. Clayburgh, Takahiro Tsujikawa and Lisa M. Coussens<br>2. Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment<br>Giosuè Scognamiglio, Mariaelena Capone, Domenico Mallardo, Gerardo Botti, Paolo A. Ascierto and Gabriele Madonna<br>3. Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images<br>Michael Surace, Lorenz Rognoni, Jaime Rodriguez-Canales and Keith E. Steele<br>4. Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ<br>Angela Vasaturo and Jérôme Galon<br>5. Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche<br>Marcus Bauer, Christoforos Vaxevanis, Daniel Bethmann, Chiara Massa, Nikolaos Pazaitis, Claudia Wickenhauser and Barbara Seliger<br>6. Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry<br>Ileana S. Mauldin, Natasha D. Sheybani, Samuel J. Young, Richard J. Price and Craig L. Slingluff<br>7. Tracing bone marrow-derived microglia in brain metastatic tumors<br>Wei Du and Paula D. Bos<br>8. Monitoring abscopal responses to radiation in mice<br>Maria Esperanza Rodriguez-Ruiz, Takahiro Yamazaki, Aitziber Buqué, Norma Bloy, Viviane A. O. Silva, Lena Stafford, Ai Sato and Lorenzo Galluzzi<br>9. Methods to assess anticancer immune responses in orthotopic bladder carcinomas<br>Randy F. Sweis<br>10. Characterization of conventional dendritic cell populations in preclinical tumor models using flow cytometry<br>Erik Wennerberg, Nils Rudqvist and Sheila Spada<br>11. Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues<br>Kathleen M. Kokolus, Nataša Obermajer and Pawel Kalinski<br>12. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption<br>Praveen K. Bommareddy, Cole Peters and Howard L. Kaufman<br>13. Production and use of adeno-associated virus vectors as tools for cancer immunotherapy<br>Myriam Fernandez-Sendin, Shirley Tenesaca, Marcos Vasquez, Fernando Aranda and Pedro Berraondo<br>14. Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition<br>João Manuel Santos, Riikka Havunen and Akseli Hemminki<br>15. Genetic modification of oncolytic viruses to enhance antitumor immunity<br>Maria Eugenia Davola, Alyssa Vito, Jiarun Wei, Nader El-Sayes, Samuel Workenhe and Karen Louise Mossman<br>16. CRISPR technology for immuno-oncology applications<br>Jianbin Wang, Vitaly Balan and Francesco Marincola<br>17. Neoantigen prediction from genomic and transcriptomic data<br>Sebastiano Battaglia<br>18. Monitoring antigen cross-presentation with human dendritic cells purified from the blood<br>Stephane Isnard, Etienne Hatton, Jean-Baptiste Guillerme and Anne Hosmalin</p>